Amevive Related Published Studies
Well-designed clinical trials related to Amevive (Alefacept)
Patterns of combination therapy with alefacept for the treatment of psoriasis in Canada in the AWARE study. [2009.12]
Efficacy outcomes in patients using alefacept in the AWARE study. [2009.12]
Alefacept for severe alopecia areata: a randomized, double-blind, placebo-controlled study. [2009.11]
Alefacept with methotrexate for treatment of psoriatic arthritis: open-label extension of a randomized, double-blind, placebo-controlled study. [2009.03]
Narrowband UV-B phototherapy, alefacept, and clearance of psoriasis. [2007.08]
The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis. [2007]
Alefacept in combination with methotrexate for the treatment of psoriatic arthritis: results of a randomized, double-blind, placebo-controlled study. [2006.05]
Results of a randomized open-label crossover study of the bioequivalence of subcutaneous versus intramuscular administration of alefacept. [2006.03.30]
An open-label study of alefacept plus ultraviolet B light as combination therapy for chronic plaque psoriasis. [2005.09]
Alefacept in the treatment of psoriasis in patients for whom conventional therapies are inadequate. [2005]
Alefacept: a novel biologic in the treatment of psoriasis. [2004.12]
Improved health-related quality of life following a randomized controlled trial of alefacept treatment in patients with chronic plaque psoriasis. [2004.02]
Remittive effects of intramuscular alefacept in psoriasis. [2003.12]
Treatment of psoriasis with alefacept: correlation of clinical improvement with reductions of memory T-cell counts. [2003.12]
CD4+ T-cell-directed antibody responses are maintained in patients with psoriasis receiving alefacept: results of a randomized study. [2003.11]
Clinical response to alefacept: results of a phase 3 study of intravenous administration of alefacept in patients with chronic plaque psoriasis. [2003.07]
Clinical response to alefacept: results of a phase 3 study of intramuscular administration of alefacept in patients with chronic plaque psoriasis. [2003.07]
An international, randomized, double-blind, placebo-controlled phase 3 trial of intramuscular alefacept in patients with chronic plaque psoriasis. [2003.06]
Alefacept therapy produces remission for patients with chronic plaque psoriasis. [2003.04]
Alefacept-induced decreases in circulating blood lymphocyte counts correlate with clinical response in patients with chronic plaque psoriasis. [2003.03]
Intramuscular alefacept improves health-related quality of life in patients with chronic plaque psoriasis. [2003]
Effects of alefacept on health-related quality of life in patients with psoriasis: results from a randomized, placebo-controlled phase II trial. [2003]
Pharmacokinetics, biologic activity, and tolerability of alefacept by intravenous and intramuscular administration. [2002.12]
A randomized, double-blind, placebo-controlled phase III study evaluating efficacy and tolerability of 2 courses of alefacept in patients with chronic plaque psoriasis. [2002.12]
Well-designed clinical trials possibly related to Amevive (Alefacept)
An update on the diagnosis and management of psoriatic arthritis. [2011]
The AWARE study: methodology and baseline characteristics. [2009.12]
Use of biologic therapeutics in difficult-to-treat psoriasis. [2009.01]
Retrospective assessment of PASI 50 and PASI 75 attainment with a calcipotriol/betamethasone dipropionate ointment. [2006.08]
Targeting T-cell subsets to achieve remission. [2003.07]
Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. [2001.07.26]
Other research related to Amevive (Alefacept)
Treatment of moderate-to-severe psoriasis with alefacept for up to one year: a case series. [2010.12]
Therapeutic hotline. Alefacept in the treatment of hyperkeratotic palmoplantar psoriasis. [2010.09]
The safety profile and sustained remission associated with response to multiple courses of intramuscular alefacept for treatment of chronic plaque psoriasis. [2010.06]
Alefacept treatment for chronic plaque psoriasis. [2010.04]
Alefacept: where it stands today. [2010.03]
Personalized medicine in psoriasis: developing a genomic classifier to predict histological response to Alefacept. [2010.02.12]
Disseminated systemic Nocardia farcinica infection complicating alefacept and infliximab therapy in a patient with severe psoriasis. [2010.02]
Update on alefacept safety. [2009.12]
Familial coexisting and colocalized psoriasis and vitiligo responding to alefacept. [2009.05]
Alefacept treatment for refractory chronic extensive GVHD. [2009.02]
A new induction protocol for the control of steroid refractory/dependent acute graft versus host disease with alefacept and tacrolimus. [2009]
Monitoring patients treated with efalizumab or alefacept. [2009]
Alefacept with methotrexate for treatment of psoriatic arthritis: Open-label extension of a randomized, double-blind, placebo-controlled study. [2008.11.22]
Alefacept in the treatment of psoriasis. [2008.09]
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. [2008.08]
An open-label pilot study of alefacept for the treatment of pyoderma gangrenosum. [2008.08]
Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. [2008.08]
Safety and efficacy of alefacept, efalizumab, etanercept and infliximab in treating moderate to severe plaque psoriasis: a meta-analysis of randomized controlled trials. [2008.06.10]
Alefacept for moderate to severe atopic dermatitis: a pilot study in adults. [2008.06]
Successful treatment of alopecia universalis with alefacept: a case report and review of the literature. [2008.05]
Alefacept for erosive lichen planus: a case series. [2008.04]
An open-label study evaluating the efficacy and tolerability of alefacept for the treatment of scalp psoriasis. [2008.04]
The safety and efficacy of high-dose alefacept compared with a loading dose of alefacept in patients with chronic plaque psoriasis. [2008.03]
Clinical effectiveness and safety experience with alefacept in the treatment of patients with moderate-to-severe chronic plaque psoriasis in Taiwan: results of an open-label, single-arm, multicentre pilot study. [2008.02.25]
A case report of Hailey-Hailey disease treated with alefacept (Amevive). [2008.02]
Alefacept revisited: Our 3-year clinical experience in 200 patients with chronic plaque psoriasis. [2008.01]
[Off-label use of biologic agents in the treatment of dermatosis, part 2: etanercept, efalizumab, alefacept, rituximab, daclizumab, basiliximab, omalizumab, and cetuximab] [2008.01]
Open label trial of alefacept in palmoplantar pustular psoriasis. [2008]
A multicenter, open-label study of repeat courses of intramuscular alefacept in combination with other psoriasis therapies in patients with chronic plaque psoriasis. [2008]
The effect of alefacept on T-cell subsets and cells expressing NK receptors in lesional psoriatic skin: the effects of monotherapy and combination treatment with calcipotriol. [2008]
Alefacept is safe and efficacious in the treatment of palmar plantar pustulosis. [2007.11]
Open-label, single-center, safety dose escalation trial of alefacept for the treatment of moderate to severe chronic plaque psoriasis. [2007.07]
Changes in circulating lymphocyte subpopulations following administration of the leucocyte function-associated antigen-3 (LFA-3)/IgG1 fusion protein alefacept. [2007.07]
Alefacept for the treatment of psoriasis and other dermatologic diseases. [2007.07]
The effect of topical corticosteroids in combination with alefacept on circulating T-cell subsets in psoriasis. [2007.06.07]
Novel insight into the agonistic mechanism of alefacept in vivo: differentially expressed genes may serve as biomarkers of response in psoriasis patients. [2007.06.01]
An open-label study to evaluate the transition of patients with chronic plaque psoriasis from cyclosporine to alefacept. [2007.04]
Explorative immunohistochemical study to evaluate the addition of a topical corticosteroid in the early phase of alefacept treatment for psoriasis. [2007.02]
Off-label uses of biologics in dermatology: rituximab, omalizumab, infliximab, etanercept, adalimumab, efalizumab, and alefacept (part 2 of 2). [2007.01]
Alefacept in corticosteroid refractory graft versus host disease: early results indicate promising activity. [2007]
Coexistent psoriasis and lupus erythematosus treated with alefacept. [2007]
Alefacept: its safety profile, off-label uses, and potential as part of combination therapies for psoriasis. [2007]
Therapeutic effects of a 12-week course of alefacept on nail psoriasis. [2006.11]
Cutaneous sarcoidosis successfully treated with alefacept. [2006.11]
Alefacept in the treatment of recalcitrant palmoplantar and erythrodermic psoriasis. [2006.09]
Alefacept in combination with ultraviolet B phototherapy for the treatment of chronic plaque psoriasis: results from an open-label, multicenter study. [2006.07]
Use of alefacept and etanercept in 3 patients whose psoriasis failed to respond to etanercept. [2006.06]
[New systemic treatments for psoriasis: etanercept, infliximab, adalimumab, efalizumab and alefacept] [2006.05.13]
Alefacept in the treatment of psoriatic nail disease: a proof of concept study. [2006.04]
Effect of calcipotriol on epidermal cell populations in alefacept-treated psoriatic lesions. [2006.01]
The efficacy of multiple courses of alefacept in patients with moderate to severe chronic plaque psoriasis. [2006.01]
An integrated analysis of thirteen trials summarizing the long-term safety of alefacept in psoriasis patients who have received up to nine courses of therapy. [2005.12]
Rapid response to alefacept given to patients with steroid resistant or steroid dependent acute graft-versus-host disease: a preliminary report. [2005.12]
Safety and efficacy of alefacept in elderly patients and other special populations. [2005.11]
Alefacept for psoriasis and psoriatic arthritis. [2005.11]
Alefacept: a safety profile. [2005.11]
Alefacept modifies long-term disease severity and improves the response to other treatments. [2005.09]
Biologic therapy for psoriasis: an update on the tumor necrosis factor inhibitors infliximab, etanercept, and adalimumab, and the T-cell-targeted therapies efalizumab and alefacept. [2005.09]
Therapy-resistant psoriasis treated with alefacept and subsequent narrow band ultraviolet B phototherapy with total clearing of psoriasis. [2005.08.01]
Treatment of palmoplantar psoriasis with intramuscular alefacept. [2005.08]
An extended 16-week course of alefacept in the treatment of chronic plaque psoriasis. [2005.07]
Treatment of psoriasis with alefacept in patients with hepatitis C infection: a report of two cases. [2005.05]
[Alefacept. Successful long-term therapy of a severe psoriasis] [2005.04]
Alefacept for the treatment of psoriasis: a review of the current literature and practical suggestions for everyday clinical use. [2005.03]
Alefacept reduces infiltrating T cells, activated dendritic cells, and inflammatory genes in psoriasis vulgaris. [2005.02.08]
Advances in therapy for psoriasis: an overview of infliximab, etanercept, efalizumab, alefacept, adalimumab, tazarotene, and pimecrolimus. [2005]
The effect of psoriasis on patients' quality of life and improvements associated with alefacept therapy. [2004.12]
Alefacept is well tolerated in patients with chronic plaque psoriasis. [2004.12]
The remittive effects of alefacept. [2004.12]
The efficacy of alefacept in the treatment of chronic plaque psoriasis. [2004.12]
Current concepts and review of alefacept in the treatment of psoriasis. [2004.10]
|
